Rational use of moxifloxacin for tuberculosis treatment

Hdl Handle:
http://hdl.handle.net/10144/129952
Title:
Rational use of moxifloxacin for tuberculosis treatment
Authors:
Cox, H; Ford, N; Keshavjee, S; McDermid, C; von Schoen-Angerer, T; Mitnick, C; Goemaere, E
Journal:
Lancet Infectious Diseases
Affiliation:
Burnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerland
Issue Date:
1-Apr-2011
URI:
http://hdl.handle.net/10144/129952
DOI:
10.1016/S1473-3099(11)70036-6
PubMed ID:
21453864
Additional Links:
http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=login
Submitted date:
2011-04-29
Type:
Article
Language:
en
ISSN:
1474-4457
Appears in Collections:
TB

Full metadata record

DC FieldValue Language
dc.contributor.authorCox, Hen
dc.contributor.authorFord, Nen
dc.contributor.authorKeshavjee, Sen
dc.contributor.authorMcDermid, Cen
dc.contributor.authorvon Schoen-Angerer, Ten
dc.contributor.authorMitnick, Cen
dc.contributor.authorGoemaere, Een
dc.date.accessioned2011-05-23T19:38:52Z-
dc.date.available2011-05-23T19:38:52Z-
dc.date.issued2011-04-01-
dc.date.submitted2011-04-29-
dc.identifier.citationLancet Infect Dis 2011;11(4):259-60en
dc.identifier.issn1474-4457-
dc.identifier.pmid21453864-
dc.identifier.doi10.1016/S1473-3099(11)70036-6-
dc.identifier.urihttp://hdl.handle.net/10144/129952-
dc.language.isoenen
dc.relation.urlhttp://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70036-6/fulltext?_eventId=loginen
dc.rightsPublished by Elsevier Reproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/journals/laninf[/url] for further relevant comment.en
dc.subject.meshTuberculosisen
dc.subject.meshTuberculosis, Multidrug-Resistanten
dc.subject.meshMoxifloxacinen
dc.titleRational use of moxifloxacin for tuberculosis treatmenten
dc.typeArticleen
dc.contributor.departmentBurnet Institute, Melbourne, Australia; Médecins Sans Frontières, Johannesburg, South Africa; Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa; Harvard Medical School, Boston, USA; Partners in Health, Boston, USA; Médecins Sans Frontières Campaign for Access to Essential Medicines, Geneva, Switzerlanden
dc.identifier.journalLancet Infectious Diseasesen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.